Results 151 to 160 of about 456,798 (336)

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Management of Immune Checkpoint Inhibitor Toxicities

Cancer Management and Research, 2020
Quentin Durrechou,1 Charlotte Domblides,1,2 Baptiste Sionneau,1 Felix Lefort,1 Amandine Quivy,1 Alain Ravaud,1 Marine Gross-Goupil,1 Amaury Daste1 1Department of Medical Oncology, Hôpital Saint-André, CHU Bordeaux-University of Bordeaux ...
Durrechou Q, Domblides C, Sionneau B, Lefort F, Quivy A, Ravaud A, Gross-Goupil M, Daste A   +7 more
doaj  

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers

Cancer Medicine, 2019
In recent years, immune checkpoint inhibitor has achieved remarkable success in multiple cancer treatment. However, how to pre‐judge which patients are suitable for immune checkpoint inhibitor is a difficult problem.
Lirong Peng, Zhanfei Chen, Yiyin Chen, Xiaoqian Wang, Nanhong Tang   +4 more
doaj   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer

Cancer Immunology, Immunotherapy
BRAF-mutated colorectal cancer correlates with poor prognosis and limited response to standard treatments. Combining immune checkpoint inhibitors with BRAF/MEK inhibitors shows promise against BRAF-mutant melanoma in both preclinical and clinical trials.
Eunyoung Tak, Hye-In An, Amy Sinyoung Lee, Kyuyoung Han, Jiwan Choi, Hyung-don Kim, Yong Sang Hong, Sun Young Kim, Eun Kyung Choi, Jeong Eun Kim, Tae Won Kim   +10 more
doaj   +1 more source

Immune checkpoint inhibitor combinations—current and emerging strategies

British Journal of Cancer, 2023
R. Walsh, R. Sundar, Joline S. J. Lim
semanticscholar   +1 more source

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source

Checkpoint inhibitors: What gastroenterologists need to know. [PDF]

, 2018
Checkpoint inhibitors are increasingly being used in clinical practice. They can cause various gastrointestinal, hepatic and pancreatic side effects. As these side effects can be serious, appropriate management is essential.
Ahmed, Monjur
core   +1 more source

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Nature Cancer, 2021
Lucile Vanhersecke, M. Brunet, J. Guégan, C. Rey, A. Bougouin, S. Cousin, S. Le Moulec, B. Besse, Y. Loriot, Mathieu Larroquette, I. Soubeyran, M. Toulmonde, G. Roubaud, S. Pernot, M. Cabart, F. Chomy, C. Lefevre, K. Bourcier, M. Kind, Ilenia Giglioli, C. Sautès-Fridman, V. Vélasco, Félicie Courgeon, Ezoglin Oflazoglu, A. Savina, A. Marabelle, J. Soria, C. Bellera, C. Sofeu, A. Bessede, W. Fridman, F. Le Loarer, A. Italiano   +32 more
semanticscholar   +1 more source